ArticleEating and weight disorders : EWD2025
Beneath the surface: unveiling the gut-brain axis in anorexia and depression.
Article in Eating and weight disorders : EWD, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anorexia nervosa (AN) and depression are complex conditions with high comorbidity, impacting mental and physical health. Recent research suggests gut microbiota plays a significant role in their development and progression. This correspondence highlights the critical gaps in understanding the gut-brain axis in AN and depression, emphasizing the need for comprehensive research. We discuss recent findings, including altered gut microbiota profiles and inflammatory factors, and identify key areas for future investigation. These include large-scale, multi-center studies to quantify microbiota profiles, mechanistic understanding of gut microbiota alterations, and diagnostic and therapeutic advances using microbiota as biomarkers. Addressing these gaps is crucial for developing effective treatment strategies and improving patient outcomes. By exploring the underlying mechanisms, validating biomarkers, and developing targeted therapies, we can enhance diagnostic accuracy, improve treatment outcomes, and better support patients with AN and depression. This research has the potential to transform the management of these conditions and improve quality of life for those affected.Level of evidence Low level of evidence as it is a personal opinion.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.